Metoprolol Succinate
Composition:Betaloc-XR-50: Each extended release tablet contains Metoprolol Succinate USP47.5mg (eqv. to Metoprolol Tartrate 50mg).
BetaIoc-XR-100:
Each extended release tablet containsMetoprolol Succinate USP 95mg (eqv. ToMetoprolol
Tartrate100mg).
Indication:
Hypertension: Extended release Metoprolol Succinate tablet is
indicated for thetreatment of hypertension. It may be used
alone or in combination with other antihypertensive agents.Angina Pectoris: Extended release Metoprolol Succinate tablet is
indicated in the long-term treatmentof angina pectoris. Heart Failure: BetaIoc-XR Tablet is
indicated for the treatment of stable, symptomatic (NYHA Class Ilor Ill) heart
failure of ischemic, hypertensive, or cardiomyopathic origin.
Dosage & Administration:Hypertension: The usual initial dosage is 25 to 100mg daily in a singledose, whether
used alone or added to a diuretic.Angina Pectoris: The dosage of extended release Metoprolol Succinate should be individualized.
Theusual initial dosage is 100mg daily, in a single dose.Heart Failure: The recommended starting dose of BetaIoc-XR is 25mg once daily for two weeks inpatients with NYHA class Il heart
failure and 12.5mg once daily in patients with more severe heart failure. The
dosage may be increased at weekly (or longer) intervals until optimum blood
pressure reduction isachieved. If treatment is to be discontinued, the dosage
should be reduced gradually over a period of(1-2 weeks). Or, as directed by the
registered physician.
Pregnancy & Lactation: There are no adequateand well-controlled studies in pregnantwomen. Metoprolol is excreted in breast milk in very small quantities. Caution should be exercisedwhen extended release Metoprolol Succinate is administered to a nursing woman.
Packing: Betaloc-XR-50: Each box contains 10 x 10's tablets in blister pack.
Betaloc-XR-100: Each
box contains 5 x 10's tablets in blister pack.
